Industry : Healthcare & Life-Sciences
Jeevatva Biosciences' core business concept revolves around the commercialization of JB-001, a novel microbiome-based therapeutic for type 2 diabetes (T2DM). Our strategy involves a two-stage market entry to maximize both early revenue and long-term market penetration. Stage 1 focuses on launching JB-001 as a premium probiotic or medical food after successful Phase 1/2 clinical trials. This allows for direct-to-consumer sales, engagement through healthcare channels, and partnerships with dietary supplement and food companies, leveraging a pricing model similar to the premium probiotic market. This stage provides early market validation and revenue streams. Stage 2 involves securing approval for JB-001 as a disease-modifying therapeutic following successful Phase 3 clinical trials. This will enable sales through medical practitioners with potential for healthcare system reimbursement and strategic collaborations with pharmaceutical companies for broader market reach. Pricing at this stage will be value-based, considering the cost of current treatments, potential savings from reduced T2DM complications, and the therapeutic label, including the potential for chronic treatment or even a cure. Our business model leverages a significant market opportunity presented by the large and growing global T2DM population. We aim to capture a substantial share of this multi-billion dollar market by offering a potentially more effective and durable solution. Our staged commercialization approach allows for early market access while simultaneously pursuing the higher-value pharmaceutical market, creating a robust and sustainable business.
Show More
Year of Establishment2023